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Abstract
The aim of this study was to evaluate the effect of Gd-chelate on renal function, iron parameters and oxidative stress in rats
with CRF and a possible protective effect of the antioxidant N-Acetylcysteine (NAC). Male Wistar rats were submitted to 5/6
nephrectomy (Nx) to induced CRF. An ionic - cyclic Gd (Gadoterate Meglumine) was administrated (1.5 mM/KgBW,
intravenously) 21 days after Nx. Clearance studies were performed in 4 groups of anesthetized animals 48 hours following
Gd- chelate administration: 12 Nx (n = 7); 22 Nx+NAC (n = 6); 32 Nx+Gd (n = 7); 42Nx+NAC+Gd (4.8 g/L in drinking water),
initiated 2 days before Gd-chelate administration and maintained during 4 days (n = 6). This group was compared with a
control. We measured glomerular filtration rate, GFR (inulin clearance, ml/min/kg BW), proteinuria (mg/24 hs), serum iron
(mg/dL); serum ferritin (ng/mL); transferrin saturation (%), TIBC (mg/dL) and TBARS (nmles/ml). Normal rats treated with the
same dose of Gd-chelate presented similar GFR and proteinuria when compared with normal controls, indicating that at this
dose Gd-chelate is not nephrotoxic to normal rats. Gd-chelate administration to Nx-rats results in a decrease of GFR and
increased proteinuria associated with a decrease in TIBC, elevation of ferritin serum levels, transferrin oversaturation and
plasmatic TBARS compared with Nx-rats. The prophylactic treatment with NAC reversed the decrease in GFR and the
increase in proteinuria and all alterations in iron parameters and TBARS induced by Gd-chelate. NAC administration to Nx rat
did not modify the inulin clearance and iron kinetics, indicating that the ameliorating effect of NAC was specific to Gd-
chelate. These results suggest that NAC can prevent Gd-chelate nephrotoxicity in patients with chronic renal failure.
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Introduction
Gadolinium-chelate (Gd) agents are used because of its
paramagnetic properties that increases the quality of images in
magnetic resonance imaging (MRI) [1]. Despite the variety of
Gadolinium based contrast, the pharmacokinetics is very similar.
The compounds are water soluble, excreted unchanged by
glomerular filtration, do not suffer biotransformation and have
good distribution in the extracellular fluid with a rapid equilibrium
between the intravascular and interstitial compartments. Notable
exceptions to these rules include gadoxetic acid and gadofosveset
trisodium. Gadoxetic acid is taken up by hepatocytes; up to 50%
of the agent is excreted in feces and 50% in urine. The chelate is
used for enhanced imaging of the liver. Between 80–96% of
circulating gadofosveset trisodium is bound to plasma proteins,
and the compound has been used as a blood pool agent [2].
The half life of Gd in patients with normal renal function is
about 1 hour and 30 minutes and over 90% of the drug is excreted
within 24 hours. Studies in patients with chronic renal failure
(CRF) show the importance of renal excretion of gadolinium.
Patients with kidney disease stage III (CrCL 31–60 ml/min) had
half-life of excretion of gadolinium approximately 5.6 hours.
Patients in stage IV (CrCL 15–30 ml/min) had half-life of 9.2
hours. In patients in stage V not on dialysis the elimination half-life
of gadolinium-chelate can reach 34.3 hours [3]. Based on their
chemical structure Gd contrast agents can be divided into 2
distinct classes: the linear and the macrocyclic agents, and based
on their charge can be divided into the ionic and the non-ionic [3].
Some toxic effects of Gd based contrast agents are attributed to the
chemical instability of the chelate and can lead to exchanges with
other metals ions notably zinc, iron or calcium [4].
The macrocyclic agents are kinetically inert under physiologic
conditions, in contrast, for the linear agents in vivo have a lower
kinetic stability. On the other hand the nonionic compounds have
a lower complex stability compared with ionic compounds. These
physical and chemical characteristics of gadolinium-chelate are
important because it has been demonstrated in vitro and in vivo
that some cations in the body as Fe3+, Zn2+, and Cu2+ has the
ability to displace the gadolinium its chelating exposing the metal
in its free form raising toxicity. This phenomenon was called
transmetallation.
Research in patients with chronic renal failure (CRF) shown
that the use of gadolinium-chelate leads to a mobilization of iron
body that can be analyzed by the kinetics of iron. In patients with
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CRF has been demonstrated that the application of gadolinium
leads to a decrease in total binding capacity of iron (TIBC),
increased serum ferritin and transferrin saturation [5–6]. Gado-
linium-mobilized iron induced nephrogenic systemic fibrosis can
be at least in part through induction of oxidative stress by Fenton
reaction [5–6].
N-acetylcysteine (NAC) is antioxidant largely employed in the
prevention of radiocontrast-induced renal failure; this effect is
mediated by the suppression of oxidative stress induced renal
tubular injury [7–9].
The purpose of the present study was to evaluate a protective
effect of NAC on nephrotoxicity caused by Gadolinium chelates in
rats with chronic renal failure.
Materials and Methods
Animals
Adult Male Wistar rats weighing between 180 and 210 g, were
provided by the University of Sa˜o Paulo School of Medicine for
use in this study. Rats were anesthetized with intraperitoneal
tribromoethanol 2.5% and were subject to either 5/6 nephrecto-
my, induced by right nephrectomy and ligation of two branches of
the left renal artery. The surgery was made in one step. The
animals were kept under standard laboratory conditions; standard
water and food were provided ad libitum. Selected rats were
treated with NAC (4.8 g/L) in drinking water, initiated 2 days
before Gd administration.
Tested Compounds
Gadolinium-chelate was approved and purchased from their
respective manufacturer:
DOTAREM H gadolinium-tetraazacyclododecanetetraacetic
acid 0,5 mmol/ml (Gd-DOTA).
Contrast Agent Administration
All rats except the normal group underwent 5/6 nephrectomy
and were anesthetized, simulating a situation of risk for
nephropathy related to radiological contrast. After 21 days of
surgery, the animals were divided into five experimental groups.
Normal (n = 8)
Normal Group + Gd (n= 8) Gadolinium was injected once at a
dose of 1.5 mmol/kg B.W. into the tail vein under anesthesia with
intraperitoneal tribromoethanol 2.5%.
Nephrectomized (Nx):
Nx: 21 days after 5/6 nephrectomized rats + N-acetylcysteine
(NAC) in drinking water (4.8 g/L) was started 2 days before
clearance study (n= 6). This dose of NAC was the same employed
in a previous study [8].
Nx + Gd - nephrectomized rats (n = 7) 21 days after
nephrectomy, gadolinium was injected once at a dose of
1.5 mmol/kg body weight (b.w.) into the tail vein under anesthesia
with intraperitoneal tribromoethanol 2.5%.
Nx+Gd+NAC - nephrectomized rats (n = 6) 21 days after
nephrectomy, gadolinium was injected once at a dose of
1.5 mmol/kg b.w into the tail vein under anesthesia with
intraperitoneal tribromoethanol 2.5%. N-acetylcysteine in drink-
ing water (4.8 g/L) was started 4 days before clearance study.
The animals were placed in metabolic cages by 24 hours after
injection of gadolinium in groups Nx, Nx+Gd, Nx+NAC and
Nx+Gd+NAC. In metabolic cages, animals had free access to
water and standard rat chow. The rats of Nx+NAC and
Nx+Gd+NAC group received NAC in their cages. All groups
remained in the metabolic cage for 24 hours. Urine was collected
for determination of proteinuria (mg/24 h).
Urine collected in metabolic cage was used for measuring total
urinary protein using the method of pyrogallol red. Proteinuria
was determined using Sensiprot Labtest Diagnostica H, through
which the urine sample was mixed with a color reagent containing
pyrogallol. The quantification of proteinuria was performed by
spectrophotometric method based on the relationship between the
absorbance of the sample and the standard solution (50 mg
protein/dL).
Blood Pressure
Before clearance studies, the animals were canulated with a PE-
60 in the carotid artery in order to measured Blood pressure by
mercury manometer.
Clearance Studies
To determine glomerular filtration rate, inulin clearance studies
were performed. On the day of experiment, the animals were
anaesthetized intraperitoneally with sodium thiopental (50 mg/kg
B.W.). The trachea was cannulated with a PE-240 catheter, and
spontaneous breathing was maintained. To control mean arterial
pressure and allow blood sampling, a PE-60 catheter was inserted
into the right carotid artery. For the infusion of inulin and fluids,
another PE-60 catheter was inserted into the left jugular vein. In
order to collect urine samples, a suprapubic incision was made,
and the urinary bladder was cannulated with PE-240 catheter.
After the surgical procedure had been completed, a loading dose
of inulin (100 mg/kg B.W. diluted in 0.9% saline) was adminis-
tered through the jugular vein. Subsequently, a constant infusion
of inulin (10 mg/kg B.W.in 0.9% saline) was started and was
continued at 0.04 ml/minute throughout the experiment. Three
urine samples were obtained at the beginning and at the end of the
experiment. Blood and urine inulin were determined using the
anthrone method. GFR are expressed as ml/min/100 g B.W. At
the end of clearance studies blood samples were collected from the
catheter inserted in the carotid artery to analysis of the iron
parameters and thiobarbituric acid reactive substances.
Analysis of the Iron Parameters
To evaluate the effect of gadolinium on the parameters of the
kinetics of iron were measured the Total Capacity Iron Binding
(TBIC, mg/dL) and serum iron (mg/dL) in nonhemolyzed serum
samples by spectrophotometric analysis using kits (Gold Analisa
Diagnostica Ltda., Brazil). Transferrin saturarion was estimated
from the ratio of serum iron to TBIC. Ferritin (ng/mL) was
measured by immunoturbidimetric assay (Gold Analisa Diagnos-
tica Ltda., Brazil).
Reactive Oxygen Metabolites
Serum levels of thiobarbituric acid reactive substances
(TBARS), which are markers of lipid peroxidation, were
determined using the thiobarbituric acid assay. In brief, a 0.2-ml
serum sample was diluted in 0.8 ml of distilled water. Immediately
thereafter, 1 ml of 17.5% trichloroacetic acid was added.
Following the addition of 1 ml of 0.6% thiobarbituric acid,
pH 2, the sample was placed in a boiling water bath for 15 min,
after which it was allowed to cool. Subsequently, 1 ml of 70%
trichloroacetic acid was added, and the mixture was incubated for
20 min. The sample was then centrifuged for 15 min at 2000 rpm.
The optical density of the supernatant was read at 534 nm against
a reagent blank using a spectrophotometer. The quantity of
TBARS was calculated using a molar extinction coefficient of
1.566105 M21 cm21.
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Statistical Analysis
Results were analyzed using ANOVA and the Student –
Newman –Keuls post hoc test using GraphPad Prism (version 3.0).
A P value ,0.05 was considered statistically significant. Data are
presented as mean 6 SEM.
Results
Normal rats treated with Gd presented a mean inulin clearance
of 0.8960.06 ml/min/100 g B.W, a value similar to untreated
normal rats (0.8260.05 ml/min/100 g B.W). The proteinuria was
not different between the 2 groups: Normal rats (4.761 mg/24 hs)
vs. Normal + Gd (5.961 mg/24 hs). The blood pressure was also
not different between the 2 groups similar (normal = 12965 vs.
normal + NAC =12664 mmHg). These results indicate that at
this dose Gd chelate is not nephrotoxic to normal rats.
The Nx+Gd group presented a higher proteinuria
(21.563.8 mg/24 hs) than the Nx group (12.861.9 mg/24 hs,
p,0.01). The proteinuria of NAC treated group was significantly
lower (11.261.0 mg/24 hs) than Nx+Gd rats (p,0.01), a value
not different from Nx group. In Nx+NAC group the proteinuria
was 10.761.5 mg/24 hs.
Blood Pressure (BP) was measured and showed no statistical
difference between the 4 groups (Nx = 16368; Nx + NAC
=161612; Nx+Gd=17068 and
Nx+Gd+NAC=151612 mmHg). Mean dose of NAC ingestion
in Nx+Gd+NAC was 72.7610.3 mg/day.
As we can see in Table 1, 48-hs after Gd administration the
inulin clearance was significantly lower in Nx+Gd rats
(0.2560.03 ml/min/100 g B.W p,0.01) when compared with
Nx-group (0.4060.03 ml/min/100 g B.W). NAC prevented the
decreased of glomerular filtration in Nx-rats treated with Gd
(0.4160.07 ml/min/100 g B.W). NAC administration to Nx rat
did not modify the inulin clearance.
The ferritin levels were significantly higher in Nx+Gd group
(47.767.2 ng/dl) than in Nx group (26.362.5 ng/dl,
p,0.05).The group Nx+Gd+NAC showed a serum ferritin level
of 28.661.3 ng/dl, similar to group Nx and lower than group
Nx+Gd (p,0.05).
The transferrin saturation in Nx+Gd group was significantly
higher than the group Nx (Nx+Gd=51.665.0% vs. Nx
= 25.262.7%, p,0.01). The group Nx + NAC+ Gd showed a
transferring saturation 32.265.6% similar to the groups Nx and
Nx+NAC, and lower than group Nx+Gd (p,0.01).
Total iron binding capacity (TIBC) in Nx+Gd group
(172612 mg/dl) was lower than Nx group (225610 mg/dl
p,0.01). The group Nx + Gd NAC showed a mean TIBC of
232610 mg/dl a value similar to Nx group and larger than
Nx+Gd group (p,0.01). Serum iron was not statistically different
between the 4 groups.
The mean serum TBARS of Nx+Gd rats was significantly
higher (3.0460.2 nmol/mL) than in Nx group (2.1460.28 nmol/
mL, p,0.05) (Fig. 1). NAC pretreatment restored the TBARS
levels to a value not significantly different from Nx
(2.0460.24 nmol/mL). These data suggest that Gd chelate
increases oxidative stress in Nx rats and that the pretreatment of
Nx+Gd rats with NAC did not increased this parameter.
Discussion
Our results demonstrate that nephrectomized 5/6 (Nx) animals
submitted to a single injection of gadolinium, showed 48 hours
after contrast administration, a significant decrease in GFR
(evaluated by the gold standard method, the inulin clearance)
and increased proteinuria rate, when compared with the 5/6 Nx
rats which did not receive Gd chelate. Furthermore, we observed
in nephrectomized rats that received gadolinium (Nx + Gd)
significant changes in the parameters of iron metabolism, ferritin,
transferrin saturation and a decrease in total iron binding capacity
(TIBC) compared to nephrectomized rats (Nx) with statistical
significance.
The administration of NAC to Nx rats which received Gd
prevented the fall in GFR and the increase of proteinuria with
gadolinium and restored the kinetic parameters of iron to values
similar to the Nx group. These effects were not due to a possible
effect of NAC on Nx, since all parameters measured in Nx+NAC
group were not different from the Nx group.
The ameliorating effect of NAC was specific to the Nx + Gd
group, since all parameters were not improved by NAC in
Nx+NAC group.
Recent studies, including in humans, have demonstrated the
potential nephrotoxicity of gadolinium [10]. Erley et al published a
prospective randomized study in patients with serum creatinine
.1.5 mg/dl, showing a decrease in GFR of around 50% of
patients exposed to gadolinium compared with 45% in patients
who received iodinated contrast [11]. Briguori et al in a
retrospective study which included a great number of patients
reported an incidence of contrast nephropathy associated to
administration of iodinated contrast agents and gadolinium
(Gadodiamide and Omniscan) dilutes with iso-osmolar iodinated
contrast media in 3: 1 parts, with around 28% compared to 6.5%
in patients who receiving only iodinated contrast [12]. Rapid
Table 1. Inulin clearance and iron parameters in Nx (nephrectomized); Nx + Gd (nephrectomized plus Gadolinium chelate); Nx Gd
+ NAC (nephrectomized plus Gadolinium chelate and N-acetylcysteine); Nx+NAC (nephrectomized plus N-acetylcysteine).
Groups Inulin clearance (ml/min/100 g) TIBC (mg/dl) Transferrin saturation (%) Ferritin (ng/ml) Serum iron (mg/dl)
Nx 0.4060.03 225610 25.262.7 26.362.7 65611
Nx+NAC 0.3660.02 230618 26.762.4 30.264.1 6064
Nx+Gd 0.2560.03b 172612b 51.665.0a 47.767.2b 8767
Nx+Gd+NAC 0.4160.07d 232610d 32.265.6e 28.663.1d 76615
Data are mean 6 s.e.m.
ap,0.001
bp,0.01
cp,0.05 vs Nx.
dp,0.05 ep,0.01 vs Nx+ Gd.
TIBC (total iron binding capacity).
doi:10.1371/journal.pone.0039528.t001
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deterioration of renal function and need of hemodialysis after Gd
administration was recently related in a diabetic patient with CRF
[13]. A recent study of the use of Gd for arterial interventions
related that the highest risk for the development of acute renal
failure occurred in patients with serum creatinine levels higher
than 3.0 mg/dL and in those receiving more than 0.4 mmol/Kg
of Gd [14].
For many years, there was no evidence of the precise
mechanism of toxicity of Gd contrast agents until the emergence
of nephrogenic systemic fibrosis. A report from Swaminathan S et
al about the pathophysiology of this disorder suggested the
involvement of oxidative stress mediated by the phenomenon of
the transmetallation of gadolinium as a mechanism responsible for
its toxicity. The transmetallation as discussed above refers to the
ability of other cations of the organism (zinc, iron, cooper and
calcium) to displace the gadolinium from its chelate and release it
in free form [5].
Swaminathan S et al demonstrated that administration of
gadolinium-chelate in patients with CRF who developed nephro-
genic systemic fibrosis (NSF) results in marked changes in iron
metabolism parameters with decreased TIBC, increased transfer-
rin saturation and serum ferritin with consequent mobilization of
body iron. They noted that beyond the CRF, patients who
developed NSF were using high doses of erythropoietin, increased
loads of body iron, elevated parathyroid hormone (PTH) and
elevated levels of systemic markers of inflammation, as cumulative
risk factors for the development of NSF [5–6].
The iron mobilized, as well as gadolinium in its free form, can
be toxic to tissues through the induction of oxidative stress
mediated by the Fenton reaction. So the latest evidence shows that
a combination of free gadolinium, iron released by Fenton
reaction, oxidative stress and inflammatory factors were possibly
involved in the pathogenesis of nephrotoxicity related to gadolin-
ium and the emergence of NSF.
All these findings indicate that studies are necessary to the
prevention of Gadolinium-chelate nephrotoxicity and to nephro-
genic systemic fibrosis in patients with chronic renal failure [15].
The use of NAC in our study was justified by its ability to
decrease the oxidative stress generated during events of cellular
stress [16–18]. N- acetylcysteine (NAC) is an antioxidant thiol that
can enter to the chain of glutathione synthesis and serves as a
source of sulfhydryl groups for the cells, acting as a scavenger of
reactive oxygen species (ROS).
TBARS is an indirect method to evaluate oxidative stress, it
represents the interaction between reactive oxidant radicals with
the lipid membrane of the cell. Previous studies have demonstrated
that TBARS levels are increased in urine of rats with CRF [17]
and in urine and plasma of patients with chronic renal failure [19–
20] and in adult primary graft recipients of deceased renal donors
[21].
In the present study, TBARS increased in Nx+Gd rats
suggesting an increase in oxidative stress induced by Gd. NAC
administration restored TBARS levels to a value similar to Nx-rats
indicating an antioxidant effect of NAC in this group.
As already expected, we did not find skin lesions in rats studied
because we use a relatively low single dose of macrocyclic
gadolinium-chelate in comparison to recent studies which used
linear and nonionic compounds several days in rats with chronic
kidney disease [22]. We studied the animals 48 hours after contrast
administration because Brillet at al demonstrated that Gd-DTPA
increased serum creatinine to a greater value 24 and 48 hs after
administration [23].
The mechanism of kidney toxicity of Dotaren, although thought
to be related to hyperosmolarity, is not entirely understood. High
osmolar radiocontrast media (sodium diatrizoate) or an equivalent
volume of isoosmolar manitol (1,100 mOsm/L) were administered
in rats with chronic NO depletion induced by pretreatment with
L-NAME during 8 weeks [24]. Radiocontrast media application
induced a significant decline in glomerular filtration rate (inulin
clearance) in L-NAME hypertensive rats whereas no effect of were
observed in mannitol-infused L-NAME hypertensive rats. Hey-
man SN et al demonstrated that iothalamate (an ionic high
osmolar agent), ioxoglate (low osmolar agent) and iohexol
(nonionic agent) produced a rise in plasma endothelin (vasocon-
Figure 1. Serum thiobarbituric acid reactive substances in groups: Nx (nephrectomized); Nx + Gd (nephrectomized plus Gadolinium
chelate); Nx Gd + NAC (nephrectomized plus Gadolinium chelate and N-acetylcysteine); Nx+NAC (nephrectomized plus N-
acetylcysteine). p,0.05 Nx vs. Nx + Gd and Nx+Gd+ NAC.
doi:10.1371/journal.pone.0039528.g001
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strictor) and induced a reduction n renal blood flow [25]. The rise
in plasma endothelin was not correlated with postinjection plasma
osmolality. In the same study plasma endothelin did not increase
after injection of hypertonic saline (2,590 mOsm/kg), glucose
(2,560 mOsm/kg) and mannitol (1,510 mOsm/kg) and the release
of endothelin from cultured endothelial cells increased with the
addition of iothalamate and iohexol, while did not change with the
addition of hypertonic saline and hypertonic glucose. These
experiments demonstrate that the decrease in GFR was indepen-
dently of osmotic load.
Since DOTA is excreted by glomerular filtration and the GFR
of the rat corrected by body weight is 5–6 fold higher than man,
we used an elevated dose of Gd-DOTA [26]. Doses of Gd-DOTA
up to 0.325 mL/Kg and even uncommon greater than 0.2 mM/
Kg were employed in patients [27].
We believe that our main result was the ability of NAC to
reverse the decline in GFR and the increase in proteinuria in rats
with CRF receiving gadolinium and prevent the mobilization of
body iron by the Fenton-transmetallation reaction. The antioxi-
dant effect of NAC can prevent gadolinium toxicity and even the
development of nephrogenic systemic fibrosis.
Future studies in patients are necessary to prove this beneficial
effect of NAC in Gd nephrotoxicity.
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